Approval · Notice of Compliance 38043 · 2026
TYENNE: Notice of Compliance 38043
Issued August 4, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38043
- Date
- August 4, 2026
- Company
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New alternate manufacturing facility for the drug product
- Canadian reference product
- ACTEMRA
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TYENNE | Not yet assigned | — |
Medicinal ingredients
- TOCILIZUMAB 162 MG per 0.9ML
- TOCILIZUMAB 162 MG per PEN